BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 28642592)

  • 21. Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.
    Bolomsky A; Hose D; Schreder M; Seckinger A; Lipp S; Klein B; Heintel D; Ludwig H; Zojer N
    J Hematol Oncol; 2015 Feb; 8():10. PubMed ID: 25887188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunoglobulin gene rearrangement in multiple myeloma: limitations of Southern blot analysis.
    Humphries JE; Dressman HK; Williams ME
    Hum Pathol; 1991 Oct; 22(10):966-71. PubMed ID: 1842385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Towards Stratified Medicine in Plasma Cell Myeloma.
    Egan P; Drain S; Conway C; Bjourson AJ; Alexander HD
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple myeloma cells promote migration of bone marrow mesenchymal stem cells by altering their translation initiation.
    Dabbah M; Attar-Schneider O; Zismanov V; Tartakover Matalon S; Lishner M; Drucker L
    J Leukoc Biol; 2016 Oct; 100(4):761-770. PubMed ID: 27272311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors.
    Jelinek T; Zihala D; Sevcikova T; Anilkumar Sithara A; Kapustova V; Sahinbegovic H; Venglar O; Muronova L; Broskevicova L; Nenarokov S; Bilek D; Popkova T; Plonkova H; Vrana J; Zidlik V; Hurnik P; Havel M; Hrdinka M; Chyra Z; Stracquadanio G; Simicek M; Hajek R
    Leukemia; 2024 Jun; 38(6):1323-1333. PubMed ID: 38493239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance.
    Vikova V; Jourdan M; Robert N; Requirand G; Boireau S; Bruyer A; Vincent L; Cartron G; Klein B; Elemento O; Kassambara A; Moreaux J
    Theranostics; 2019; 9(2):540-553. PubMed ID: 30809292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular biology of myeloma.
    Gutiérrez NC; García-Sanz R; San Miguel JF
    Clin Transl Oncol; 2007 Oct; 9(10):618-24. PubMed ID: 17974522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination.
    Garcés JJ; Simicek M; Vicari M; Brozova L; Burgos L; Bezdekova R; Alignani D; Calasanz MJ; Growkova K; Goicoechea I; Agirre X; Pour L; Prosper F; Rios R; Martinez-Lopez J; Millacoy P; Palomera L; Del Orbe R; Perez-Montaña A; Garate S; Blanco L; Lasa M; Maiso P; Flores-Montero J; Sanoja-Flores L; Chyra Z; Vdovin A; Sevcikova T; Jelinek T; Botta C; El Omri H; Keats J; Orfao A; Hajek R; San-Miguel JF; Paiva B
    Leukemia; 2020 Feb; 34(2):589-603. PubMed ID: 31595039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. One-lincRNA and five-mRNA based signature for prognosis of multiple myeloma patients undergoing proteasome inhibitors therapy.
    Liu Y; Yang N; Peng X; Liu G; Zhong H; Liu L
    Biomed Pharmacother; 2019 Oct; 118():109254. PubMed ID: 31357080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic deep-targeted next-generation sequencing assessment of TP53 gene mutations in multiple myeloma from the whole bone marrow.
    Petrackova A; Minarik J; Sedlarikova L; Libigerova T; Hamplova A; Krhovska P; Balcarkova J; Pika T; Papajik T; Kriegova E
    Br J Haematol; 2020 May; 189(4):e122-e125. PubMed ID: 32130732
    [No Abstract]   [Full Text] [Related]  

  • 31. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.
    Rasche L; Chavan SS; Stephens OW; Patel PH; Tytarenko R; Ashby C; Bauer M; Stein C; Deshpande S; Wardell C; Buzder T; Molnar G; Zangari M; van Rhee F; Thanendrarajan S; Schinke C; Epstein J; Davies FE; Walker BA; Meissner T; Barlogie B; Morgan GJ; Weinhold N
    Nat Commun; 2017 Aug; 8(1):268. PubMed ID: 28814763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.
    Besse L; Sedlarikova L; Kryukov F; Nekvindova J; Radova L; Slaby O; Kuglik P; Almasi M; Penka M; Krejci M; Adam Z; Pour L; Sevcikova S; Hajek R
    PLoS One; 2015; 10(9):e0137294. PubMed ID: 26389804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomics in multiple myeloma: biology and clinical implications.
    Chng WJ; Fonseca R
    Pharmacogenomics; 2005 Sep; 6(6):563-73. PubMed ID: 16142997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of novel fusion transcripts in multiple myeloma.
    Lin M; Lee PL; Chiu L; Chua C; Ban KHK; Lin AHF; Chan ZL; Chung TH; Yan B; Chng WJ
    J Clin Pathol; 2018 Aug; 71(8):708-712. PubMed ID: 29453220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
    Manier S; Kawano Y; Bianchi G; Roccaro AM; Ghobrial IM
    Curr Opin Hematol; 2016 Jul; 23(4):426-33. PubMed ID: 27101529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of genomics on the management of myeloma.
    Corre J; Avet-Loiseau H
    J Natl Compr Canc Netw; 2011 Oct; 9(10):1200-6. PubMed ID: 21975916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene expression profiling and multiple myeloma.
    Shaughnessy J; Zhan F; Barlogie B; Stewart AK
    Best Pract Res Clin Haematol; 2005; 18(4):537-52. PubMed ID: 16026736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis.
    Boiarsky R; Haradhvala NJ; Alberge JB; Sklavenitis-Pistofidis R; Mouhieddine TH; Zavidij O; Shih MC; Firer D; Miller M; El-Khoury H; Anand SK; Aguet F; Sontag D; Ghobrial IM; Getz G
    Nat Commun; 2022 Nov; 13(1):7040. PubMed ID: 36396631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ultradeep, targeted sequencing reveals distinct mutations in blood compared to matched bone marrow among patients with multiple myeloma.
    Coffey DG; Wu QV; Towlerton AMH; Ornelas S; Morales AJ; Xu Y; Green DJ; Warren EH
    Blood Cancer J; 2019 Sep; 9(10):77. PubMed ID: 31570697
    [No Abstract]   [Full Text] [Related]  

  • 40. Established and Novel Prognostic Biomarkers in Multiple Myeloma.
    Bustoros M; Mouhieddine TH; Detappe A; Ghobrial IM
    Am Soc Clin Oncol Educ Book; 2017; 37():548-560. PubMed ID: 28561668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.